Loading clinical trials...
Loading clinical trials...
A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Conditions
Interventions
4 mg/kg Onartuzumab (MetMAb)
15 mg/kg Onartuzumab (MetMAb)
+1 more
Locations
3
China
Beijing Cancer Hospital
Beijing, China
the First Hospital of Jilin University
Changchun, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Start Date
January 13, 2014
Primary Completion Date
April 14, 2014
Completion Date
April 14, 2014
Last Updated
March 14, 2017
NCT07213804
NCT07169851
NCT00026884
NCT07159659
NCT07191730
NCT06662786
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions